COMMUNIQUÉS West-GlobeNewswire

Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format

16/12/2024 - 14:37

The term sheet is non-binding, subject to the execution of a definitive agreement Vancouver, Canada, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), [...]

Nova Leap Health Corp. announces Closing of Strategic Acquisition in Florida

16/12/2024 - 14:33

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Dec. 16, 2024 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) ("Nova Leap" or “the Company”), a [...]

BioSyent Announces Renewal of Normal Course Issuer Bid

16/12/2024 - 14:30

MISSISSAUGA, Ontario, Dec. 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the Company’s Notice of [...]

Treace Announces First Surgical Cases Utilizing the SpeedPlate™ MicroQuad™ Implant

16/12/2024 - 14:30

PONTE VEDRA, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]

Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

16/12/2024 - 14:30

CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, [...]

New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26

16/12/2024 - 14:30

- Results for all three TransCon hGH starting dose cohorts, in first clinical trial of an indication outside of growth hormone deficiency, showed a safety and tolerability profile comparable to daily somatropin - [...]

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

16/12/2024 - 14:30

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for [...]

Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

16/12/2024 - 14:09

SARASOTA, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE: OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today announced the conversion of its [...]

Pharming announces public cash offer to the shareholders of Abliva AB

15/12/2024 - 19:45

Proposed acquisition strengthens Pharming’s late-stage pipeline with a potential first-in-disease asset Abliva’s lead product KL1333 is currently in a pivotal clinical trial, with a positive interim analysis achieved, [...]

Kellner Group Denounces False Rumors About AIM Short Selling and Demands Immediate Accountability from Incumbent Board

14/12/2024 - 22:54

Vote “ FOR ” All Four Kellner Group Nominees Today on Gold Card for Urgently Needed Change Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with Stockholders NEW YORK, Dec. 14, 2024 (GLOBE NEWSWIRE [...]

Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close

14/12/2024 - 06:08

Bagsværd, Denmark, 14 December 2024 — As of today, all regulatory closing conditions relating to the review of Novo Holdings A/S’s pending acquisition of Catalent, Inc. (Catalent), including expiry of the timing [...]

Rakovina Therapeutics Announces Closing of Oversubscribed $3M Private Placement

14/12/2024 - 00:50

VANCOUVER, British Columbia, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “ Company ”, “ Rakovina ”, or “ Rakovina Therapeutics ”) a biopharmaceutical company committed to advancing new [...]

Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)

14/12/2024 - 00:15

UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: [...]

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

13/12/2024 - 23:16

NAARDEN, The Netherlands and MIAMI, Dec. 13, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, [...]

Nova Leap Health Corp. provides update on Special Meeting

13/12/2024 - 23:01

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Dec. 13, 2024 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a [...]

Edesa Biotech Reports Fiscal Year 2024 Results

13/12/2024 - 22:30

TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported [...]

MEDIROM Healthcare Technology‘s Subsidiary, MEDIROM MOTHER Labs, Raises an Aggregate Total of JPY260.3 Million in its Series A Financing Round

13/12/2024 - 22:30

Pre-Money Valuation of JPY9 Billion is Approximately Multiples of Current Parent Company Market Capitalization. Strategic Investors Further Validation of Technology and Growth Potential. Further Commercialization with [...]

Outlook Therapeutics® Streamlines Operations

13/12/2024 - 22:30

Full NORSE EIGHT Data Readout Expected January 2025 ISELIN, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the [...]

CorVel Announces Three-For-One Forward Stock Split and Authorized Share Increase

13/12/2024 - 22:15

FORT WORTH, Texas, Dec. 13, 2024 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL) announces that its Board of Directors approved a three-for-one forward stock split of its common stock. The Board also approved a [...]